Skip to main navigation Skip to search Skip to main content

The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report

  • National High Blood Pressure Education Program Coordinating Committee
  • Boston University
  • Rush University Medical Center
  • University of Tennessee Health Science Center
  • University of Michigan, Ann Arbor
  • University of Mississippi
  • University of Miami
  • University of Alabama at Birmingham
  • Case Western Reserve University
  • American Institutes for Research
  • National Institutes of Health
  • University of Iowa
  • Saint Louis University
  • American Podiatric Medical Association, Inc.
  • Healthcore, Inc.
  • American Academy of Physician Assistants
  • Heartbeats Life Center
  • Cleveland Clinic Foundation
  • University of Maryland, Baltimore
  • Sanofi-Synthelabo Research
  • East Carolina University
  • University of Colorado Anschutz Medical Campus
  • New York University
  • Indiana University Bloomington
  • United States Department of Health and Human Services
  • Stanford University
  • Yale University
  • Philadelphia College of Osteopathic Medicine
  • Howard University
  • Morehouse School of Medicine
  • National Stroke Association
  • Mayo Clinic Rochester, MN
  • SUNY Downstate Health Sciences University
  • Eye Group
  • Procter and Gamble
  • New York Institute of Technology
  • Baylor College of Medicine
  • Georgetown University
  • Mayo Clinic College of Medicine
  • Inc
  • American Heart Association

Research output: Contribution to journalReview articlepeer-review

17757 Scopus citations

Abstract

"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure" provides a new guideline for hypertension prevention and management. The following are the key messages: (1) In persons older than 50 years, systolic blood pressure (BP) of more than 140 mm Hg is a much more important cardiovascular disease (CVD) risk factor than diastolic BP; (2) The risk of CVD, beginning at 115/75 mm Hg, doubles with each increment of 20/10 mm Hg; individuals who are normotensive at 55 years of age have a 90% lifetime risk for developing hypertension; (3) Individuals with a systolic BP of 120 to 139 mm Hg or a diastolic BP of 80 to 89 mm Hg should be considered as prehypertensive and require health-promoting lifestyle modifications to prevent CVD; (4) Thiazide-type diuretics should be used in drug treatment for most patients with uncomplicated hypertension, either alone or combined with drugs from other classes. Certain high-risk conditions are compelling indications for the initial use of other antihypertensive drug classes (angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, β-blockers, calcium channel blockers); (5) Most patients with hypertension will require 2 or more antihypertensive medications to achieve goal BP (<140/90 mm Hg, or <130/80 mm Hg for patients with diabetes or chronic kidney disease); (6) If BP is more than 20/10 mm Hg above goal BP, consideration should be given to initiating therapy with 2 agents, 1 of which usually should be a thiazide-type diuretic; and (7) The most effective therapy prescribed by the most careful clinician will control hypertension only if patients are motivated. Motivation improves when patients have positive experiences with and trust in the clinician. Empathy builds trust and is a potent motivator. Finally, in presenting these guidelines, the committee recognizes that the responsible physician's judgment remains paramount.

Original languageEnglish
Pages (from-to)2560-2572
Number of pages13
JournalJAMA
Volume289
Issue number19
DOIs
StatePublished - May 21 2003

Fingerprint

Dive into the research topics of 'The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report'. Together they form a unique fingerprint.

Cite this